PRESS RELEASE published on 03/07/2025 at 08:29, 1 year 4 months ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics announces c. €0.9 million financing round for innovative gene therapy program. Financing from existing investors supports LUMEVOQ access for patients. Business update includes 2024 annual results and working capital statement Financing Business Update Gene Therapy GenSight Biologics LUMEVOQ
BRIEF published on 02/27/2025 at 09:02, 1 year 5 months ago GenSight Biologics: 2024 Financial Results and Outlook Gene Therapy Cash Management Financial Results 2024 Future Financing LUMEVOQ Compassionate Access
PRESS RELEASE published on 02/27/2025 at 08:57, 1 year 5 months ago Inside Information / News release on accounts, results GenSight Biologics reports estimated full-year 2024 consolidated financial results. Cash runway extended to early April 2025. Resumption of Compassionate Access Program expected in April 2025 Financial Results 2024 GenSight Biologics Cash Runway Compassionate Access Program
BRIEF published on 02/12/2025 at 07:35, 1 year 5 months ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 5 months ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 1 year 6 months ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 6 months ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 1 year 6 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 6 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
Published on 08/01/2026 at 01:20, 1 day 19 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 1 day 19 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 1 day 20 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 1 day 21 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/02/2026 at 08:15, 12 hours 27 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 1 day 4 hours ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 19:55, 2 days ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA Reaches Agreement with Financing Partners on Extension of Standstill Agreement and Continuation of Restructuring Process
Published on 07/31/2026 at 19:05, 2 days 1 hour ago Eurobattery Minerals presents the Q2 report for 2026 as the Company accelerates the development of the San Juan tungsten project
Published on 07/31/2026 at 21:00, 1 day 23 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:13, 2 days 1 hour ago Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
Published on 07/31/2026 at 18:30, 2 days 2 hours ago Covivio Hotels - 2026 Half-year financial report
